期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤基因治疗的腺病毒策略 被引量：4

Adenoviral strategies for the gene therapy of tumor
原文传递
导出
摘要 腺病毒载体是目前肿瘤临床试验中使用最为广泛的载体之一。在过去的十几年里，随着人们对腺病毒活动周期的逐步了解，已经开发出了一系列专门针对恶性肿瘤细胞的靶向腺病毒载体。这些载体可以在特定的细胞中表达治疗性基因或进行自主复制，显示了其在肿瘤治疗方面的独特优势。但目前对腺病毒进行的各种改进方式都存在不同程度的缺陷，因此仍需进一步研究。文章讨论腺病毒载体用于肿瘤基因治疗方面的一些基本情况及其在临床应用的潜力。 Adenoviral vectors are one of the most popular vehicles for gene transfer currently being used in worldwide clinical trails for cancer, Over the past decade our knowledge of the adenoviral life cycle has permitted the targeting of adenoviral vectors to specific tumors, it can be manipulated to express therapeutic genes or to replicate specifically in certain cells. A variety of virus vectors have been employed to deliver genes to cells to provide either transient or permanent transgenes expression and each approach has its own advantages and disadvantages. This review discuss the basic concepts behind the use of adenoviral vectors for cancer gene therapy and their potential for clinical application.
作者 张建军(综述) 钱关祥(审校) 葛盛芳(审校)
机构地区 上海交通大学医学院生物化学与分子生物学研究室、人类基因治疗研究中心
出处 《肿瘤研究与临床》 CAS 2007年第1期63-65,共3页 Cancer Research and Clinic
基金 国家自然基金资助项目（30400536） 国家重大基础研究资助项目（2004CB518804）.
关键词 肿瘤 基因疗法 腺病毒 人 Tumor Gene therapy Adenoviruses,human
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Kay M A, Holteman A X, Meuse L, et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration[J]. Nat Genet, 1995, 11(2): 191-197.
  • 2Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology ofrecombination adenovirus vectors with E1,E1/E2A,or El/E4 deleted[J]. J Virol, 1998, 72(3): 2022-2032.
  • 3Parks R J. Chen L, Anton M, et al. A helper-dependent adenovirusvector system:removal of helper virus by Cre-mediated excision ofthe viral packaging signal[J]. Proc Natl Acad Sci USA, 1996, 93(24): 13565-13570.
  • 4Kasono K, Blackwell J L, Douglas J T, et al. Selective gene deliv-ery to head and neck cancer via an integrin targeted adenoviralvector[J]. Clln Cancer Res, 1999, 5(9): 2571-2579.
  • 5Barnett B G, Crews C J, Douglas J T, Targeted adenoviral vectors[J],Biochim Biophys Acta, 2002, 1575(1-3): 1-14.
  • 6Jacob D, Bahra M, Schumacher G, et al. Gene therapy in coloncancer cells with a fiber-modified adenovector expressing theTRAIL gene driven by the hTERT promoter [J]. Anticancer Res,2004, 24(5A): 3075-3079.
  • 7Kawakami Y, Li H, Lam J T, et al. Substitution of the adenovirusserotype 5 knob with a serotype 3 knob enhance multiple steps invirus replication[J]. Cancer Res, 2003, 63(6): 1262-1269.
  • 8Rodriguez R, Schuur E R, Lim H Y, et al. Prostate attenuatedreplication competent adenovirus (ARCA)CN706:a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells [J].Cancer Res, 1997, 57(13): 2559-2563.
  • 9Yu D C, Chen Y, Seng M, et al. The addition of adenovirus type 5region E3 enables calydon virus 787 to eliminate distant Prostatetumor xenograft[J]. Cancer Res, 1999, 59(17): 4200-4203.
  • 10Ren X W, Liang M, Meng X. A tumor-specific conditionallyreplicative adenovims vector expressing TRALL for gene therapy ofhepatocellular carcinoma[J]. Cancer Gene Ther, 2006, 13(2): 159-168.

二级参考文献17

  • 1Russell WC. Update on adenovirus and it′s vectors. J Gen Virol, 2000,81:2573-2604.
  • 2Dominik Wodarz. Viruses as antitumor weapons: Defining conditions for tumor remission. Cancer Res, 2001, 61:3501-3507.
  • 3Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest,2000,106:763-771.
  • 4Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 2001,269:1-12.
  • 5Su CQ, Xue HB, Wang XH, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting to the telomerase-positive cancer cells. J cancer Research and Clinical Oncology.J Cancer Res Clin Oncol, 2004,130:591-603.
  • 6Bischoff JR, Kirn DH,Williams A. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science, 1996,274:373-376.
  • 7Khuri F, Nemunaitis J,Ganly I. et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 2000, 6:879-885.
  • 8Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer, 1997, 33:787-791.
  • 9Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther, 2004,11: 174-185.
  • 10Huang TG, Savontaus MJ, Shinozaki K, et al. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther, 2003,10: 1241-1247.

共引文献40

同被引文献45

引证文献4

二级引证文献1

肿瘤研究与临床
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部